Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 9/20 | 0.61 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.61 |
| ▸ | HTR1A | P08908 | 7/20 | 0.54 |
| ▸ | HTR7 | P34969 | 7/20 | 0.54 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6795995 | 0.84 | MDM2 (0.54) | PARP1PARP2HTR1AHTR7TSHR | |
| SCHEMBL6793345 | 0.79 | MDM2 (0.59) | PARP1PARP2 | |
| SCHEMBL6791766 | 0.76 | TNKS2 (0.59) | PARP1PARP2TSHR | |
| SCHEMBL14981676 | 0.76 | PARP1 (1.00) | PARP1PARP2HTR1AHTR7 | |
| SCHEMBL30176876 | 0.74 | PARP1 (0.73) | PARP1PARP2HTR1AHTR7 | |
| SCHEMBL30176852 | 0.74 | PARP1 (0.73) | PARP1PARP2HTR1AHTR7 | |
| SCHEMBL31060680 | 0.74 | PARP1 (1.00) | PARP1PARP2HTR1AHTR7 | |
| SCHEMBL30176871 | 0.73 | TNKS2 (0.57) | PARP1PARP2TSHRSMN1; SMN2 | |
| SCHEMBL6795915 | 0.73 | PARP1 (0.70) | PARP1PARP2HTR1AHTR7 | |
| SCHEMBL7102398 | 0.73 | GRIN2B (0.74) | HTR1AHTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040077667-A1 | Quinazolinone derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-04-22 | — | — | US | disclosed |
| CN-1489581-A | Quinazolinone derivatives | ����ҩƷ��ҵ��ʽ���� | 2004-04-14 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040077667-A1 | Quinazolinone derivatives | PARP1, PARP9, PARP2 | PARP1 1/4885PARP2 3/4885HTR1A 848/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.